middle.news
Radiopharm Theranostics Advances Phase 1 Trial of 177Lu-RAD202 to Next Dose Level
9:10am on Wednesday 8th of April, 2026 AEST
•
Healthcare
Read Story
Radiopharm Theranostics Advances Phase 1 Trial of 177Lu-RAD202 to Next Dose Level
9:10am on Wednesday 8th of April, 2026 AEST
Key Points
Positive Data Safety and Monitoring Committee recommendation for dose escalation to 130mCi
Phase 1 ‘HEAT’ trial progressing rapidly with favorable safety profile
177Lu-RAD202 targets HER2-positive advanced solid tumors including breast cancer
Dose escalation expected to complete by end of 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE